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To identify candidate genes that may be involved in motoneuron degeneration, we combined laser capture
microdissection with microarray technology. Gene expression in motoneurons was analyzed during the pro-
gression of the disease in transgenic SOD1G93A mice that develop motoneuron loss. Three major obser-
vations were made: first, there was only a small number of genes that were differentially expressed in
motoneurons at a pre-symptomatic age (27 out of 34 000 transcripts). Secondly, there is an early specific
up-regulation of the gene coding for the intermediate filament vimentin that is increased even further
during disease progression. Using in situ hybridization and immunohistochemical analysis, we show that
vimentin expression was not only elevated in motoneurons but that the protein formed inclusions in the
motoneuron cytoplasm. Thirdly, a time-course analysis of the motoneurons at a symptomatic age (90 and
120 days) showed a modest de-regulation of only a few genes associated with cell death pathways; however,
a massive up-regulation of genes involved in cell growth and/or maintenance was observed. This is the first
description of the gene profile of SOD1G93A motoneurons during disease progression and unexpectedly, no
widespread induction of cell death-associated genes was detected in motoneurons of SOD1G93A mice.
INTRODUCTION
One of the key features in the understanding of neurodegenera-
tive diseases such as amyotrophic lateral sclerosis (ALS) is to
elucidate mechanisms that underlie or predispose one particular
type of neuron (i.e. amotoneuron) to selective death (for review,
see (1)). One means of analyzing this selective vulnerability
consists in studying gene expression alterations in motoneur-
ons during disease progression. Certain obstacles in analyzing
tissue from the nervous system result from the wide variety of
cell types. The cell heterogeneity of the brainstem and the
spinal cord interferes with an analysis of the molecular
changes occurring in a specific subpopulation of cells.
However, the emerging technology of laser capture microdis-
section (LCM) allows procurement of specific cells from
tissue sections that can be used to profile gene expression.
Furthermore, the simultaneous comparison of the expression
profiles of thousands of genes can be achieved using
microarrays.
Recently, Sobue and coworkers (2) have applied these
techniques to analyze the gene expression profile of human
spinal motoneurons in sporadic ALS tissue. As expected,
spinal motoneurons showed a unique gene expression profile
compared with the whole ventral spinal cord. Down-regulated
genes were related to cytoskeletal and axonal transport,
whereas up-regulated genes were associated with both promo-
ters and inhibitors of cell death pathways. Inflammation-
related genes were not significantly up-regulated.
A great deal of gene expression analysis has been done in
the entire spinal cord of the SOD1G93A mouse model that
expresses a human mutated SOD1 gene and represents a
mouse model for familial ALS (3,4). These studies showed a
wide variety of modifications in a large spectrum of genes.
In contrast, no analysis has been done on pure motoneurons.
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Some controversy has been generated about whether the death
phenomenon is indeed cell autonomous; when the SOD1
mutant gene is expressed either in the astrocytes or in the
neurons, no motoneuron degeneration occurs (5–7). More
recent studies by Clement et al. (8) showed that toxicity to
motoneurons requires mutant damage not just within moto-
neurons but also to non-neuronal cells. Furthermore, normal
non-neuronal cells can protect motoneurons that express the
mutated SOD1 gene, suggesting that SOD1-mediated toxicity
is non-cell autonomous.
In this study, we combined LCM and microarrays to
identify modifications in gene expression in microdissected
motoneurons issued from control and SOD1G93A mice. At a
pre-symptomatic age (60 days), there was a modest number
of de-regulated genes; only 27 out of 34 000 transcripts
showed a differential expression. Secondly, the intermediate
filament, vimentin, was up-regulated at all stages of the
disease not only in SOD1G93A mice but also in two other
mouse models that exhibit an inherited loss of motoneurons
(progressive motor neuronopathy and wobbler). Finally, an
analysis of SOD1G93A motoneurons during disease pro-
gression (early symptomatic age, 90-day-old; end stage of
disease, 120 days of age) showed a modest de-regulation of
only three genes associated with cell death pathways (XIAP,
caspase-1 and -3), but a massive up-regulation of genes
involved in cell growth and/or maintenance. These results
demonstrate that there is no widespread activation of genes
involved in cell death pathways in SOD1G93A motoneurons.
RESULTS
Motoneuron isolation by LCM
To identify early modifications in gene expression that may
predispose or trigger motoneuron death, it was important to
study the differential gene expression that may occur during
early events of motoneuron degeneration. We microdissected
motoneurons from the lumbar spinal cord (L2–L5) of
SOD1G93A mice where the onset of degeneration occurs. As
SOD1G93A mice show the first clinical evidence of disease
at approximately 80 days of age, we undertook our initial
analysis at a pre-symptomatic age (60 days of age). Gene
expression profiles were subsequently analyzed during the
progression of the disease in lumbar motoneurons at an
early symptomatic age (90 days of age) and at end stage of
the disease (120 days of age).
Motoneurons were selected according to (i) their localiz-
ation in the ventral part of the spinal cord (Fig. 1A and B),
(ii) a diameter of at least 25 mm and (iii) an identifiable
nucleus (Fig. 1C). The remaining spinal cord tissue was
intact after the laser-capture procedure (Fig. 1B and D),
proving the high selectivity of the microdissection. The mor-
phology of the motoneurons was analyzed on cresyl violet
stained sections. At 60 days of age, motoneurons appeared
similar in control and mutant mice; they had not undergone
visible neurodegeneration, were not atrophic and showed no
characteristic features of apoptosis such as cell shrinkage
and nuclear condensation (Fig. 1E and F). At 120 days of
age, motoneurons in mutant mice showed characteristics of
degeneration and/or atrophy (Fig. 1H). In control animals, at
all ages, motoneurons with a diameter of at least 25 mm
represented 52+ 3% of the total motoneurons on a given
section. At a pre-symptomatic age in mutant animals, the
diameter of motoneurons remained unchanged (50.7+ 0.8%)
whereas at symptomatic ages, motoneurons with a diameter
of at least 25 mm represented 43.3+ 1.3 and 38.6+ 7% at
90 and 120 days of age, respectively.
To confirm the high selectivity of microdissection, we
examined by quantitative real-time PCR (Q-PCR) the
expression levels of motoneuron markers in both the lumbar
Figure 1. LCM of motoneurons from a methylene blue-stained section of 60-
day-old SOD1G93A spinal cord and morphological characteristics of motoneur-
ons during disease progression. (A) Motoneurons localized in the ventral part
of the spinal cord before capture. The ventral part is on the right and the dorsal
part on the left. Sections are from the lumbar (L2–L5) of SOD1G93A spinal
cord. (B) Spinal cord after capture of motoneurons. (C and D) Higher magni-
fication of (A) and (B). (C) Selected motoneurons for the capture. (D) Spinal
cord after capture. Tissue surrounding the captured cells remains intact after
microdissection. Scale bar represents 100 mm in (A) and (B); 25 mm in (C)
and (D); 30mm in (E) and (F). (E and F) Cresyl violet staining of lumbar
(L2–L5) spinal cord in 60-day-old control and SOD1G93A mice. Motoneurons
appeared similar in controls and mutant mice. Motoneurons in mutant mice
do not show any characteristics of degeneration or atrophy. (G and H)
Cresyl violet staining of lumbar (L2–L5) spinal cord in 120-day-old
control and SOD1G93A mice. (H) Motoneurons in mutant mice show character-
istics of degeneration or atrophy. (E and G) Control mice. (F and H)
Mutant mice.
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spinal cord and purified motoneurons. Choline acetyltransfer-
ase, a bona fide motoneuron marker, was expressed 25-fold
more in motoneurons than in spinal cord. The expression of
calcitonin-related polypeptide and neurofilament heavy
subunit was increased 6- and 3-fold, respectively, in purified
motoneurons. These enrichment ratios provided strong
evidence for the specificity of the dissection.
Quality of initial and amplified RNAs
As the quality of the starting RNA is a prerequisite for further
genomic analysis, we first demonstrated that LCM did not
interfere with the quality of total RNA (Fig. 2A). All
samples were tested and only those with ‘high-quality’ RNA
were used. As our starting material consists of 2000–2400
cells, it was only possible to extract a small amount of RNA
(40 ng); thus it was necessary to do a double amplification pro-
cedure before microarray analysis. We controlled the quality
of the RNA from the first (Fig. 2B) and second amplifications
(Fig. 2C) and found that their amplification profiles were
similar. The ‘smear’ was comprised all lengths of amplified
RNA (from 60 to 4000–5000 bp) with a peak of 500 bp
after both procedures (Fig. 2B and C), indicating a high
quality of amplification.
A small number of genes were differentially expressed in
SOD1G93A motoneurons at a pre-symptomatic age
We compared the molecular profile of 2000–2400 microdis-
sected motoneurons from both mutant and control mice in
order to identify genes that were differentially expressed.
Motoneurons were pooled from one mouse per array, and
three arrays were analyzed in both mutants and controls;
34 000 transcripts were examined on the gene chips. Among
those transcripts, only 27 genes (0.08% of the screened
genes) were differentially expressed in SOD1G93A motoneur-
ons (Table 1).
Seventeen transcripts, including the genes for matrix metal-
loproteinase 13, myristoylated alanine-rich protein kinase C
substrate (coding for a major protein kinase C substrate in the
brain), the nephroblastoma overexpressed gene [coding for an
insulin-like growth factor binding protein (IGFBP)], growth-
associated protein 43, vimentin (an intermediate filament type
III) and gap junction channel protein alpha (connexin 43),
were up-regulated (Table 1). Eleven transcripts, including
tubulin alpha 3 gene, ionotropic glutamate receptor N-
methyl-D-aspartic acid (NMDA) zeta 1 and carbonic anhydrase
gene, were down-regulated. All these genes belong to various
families of proteins such as intermediate filaments, protein
catabolism, cell communication and regulators of cell growth.
Independent validation of candidate genes at a
pre-symptomaticage using quantitative real-time PCR
To determine the reliability of our microarray analysis and to
reduce the number of false-positive candidates, we selected
eight differentially expressed genes and examined their
expression levels by quantitative real-time PCR using ampli-
fied cRNA samples issued from separate batches of microdis-
sected motoneurons. We confirmed the differential expression
obtained by microarrays for five of these eight genes, indicat-
ing that three genes were false positives (Table 2).
As some of the de-regulated genes such as vimentin and
connexin 43 are also known to be expressed in glia cells, we
Figure 2. Quality of initial and amplified RNAs. The Agilent LabChip tech-
nology was used to control the quality of the RNA. In all graphs, the first
peak corresponds to an internal marker of 25 nucleotides. (A) For each exper-
iment, the integrity of total RNA from the LCM samples was determined. This
graph shows that the two most representative peaks of rRNA (18S and 28S)
are well defined; moreover, the ratio 28S/18S is approximately 2 which is
an indication of high-quality total RNA. For each sample, we obtained a
profile that is representative of intact RNA. (B) RNA quality after the first
amplification. (C) RNA quality after the second amplification. The ‘smear’
is comprised of all lengths of RNA, indicating that we have obtained a
good quality of amplified RNA after one round of amplification (B) as well
as after the second round of amplification (C).
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examined their expression level by real-time PCR in entire
segments of the spinal cord (L2–L5). None of these genes
showed a modified expression in the whole spinal cord, con-
firming the specificity of the differential expression within
pure motoneurons. Indeed, vimentin was not de-regulated in
the entire lumbar spinal cord (1.01+ 0.1) but showed a 1.79
(+0.02)-fold increase in microdissected motoneurons; simi-
larly, connexin 43 did not show a de-regulation in the spinal
cord (21.22+ 0.22).
Genes differentially expressed in SOD1G93A motoneurons
during disease progression
Using microarrays, we analyzed the molecular profile of
microdissected motoneurons from SOD1G93A mice at an
early post-symptomatic age (90 days) and at the end stage
of the disease (120 days); 34 000 transcripts were examined
on the gene chips. There was a de-regulation of approximately
150 genes at the onset of the disease (90 days) and more
than 400 genes at 120 days of age. At both ages, the majority
of the de-regulated genes were up-regulated (95 and 389,
respectively) and only a minority down-regulated (53 at both
ages).
We then compared the de-regulated genes at all stages of
the disease (Fig. 3). Among all de-regulated genes, nine
were up-regulated (including matrix metalloproteinase 13,
vimentin, nephroblastoma overexpressed gene (NOV), serine
proteinase inhibitor, growth-associated protein 43, aquaporin
4, myristoylated alanine-rich protein kinase C substrate and
cathepsin Z) (Fig. 3A, Table 1; Supplementary Material,
Table S1) and three down-regulated (general receptor for
phosphoinositides-1-associated scaffold protein, immuno-
globulin heavy chain 6 and glutamate ionotropic receptor,
NMDA1) (Fig. 3B, Table 1; Supplementary Material,
Table S1) at all stages of the disease. These values correspond
to 52.9% (9/17) and 27% (3/11), respectively, of the differ-
entially regulated genes identified by microarrays at a pre-
symptomatic age. When we compared the differential
expression at an early symptomatic age (90 days) and at the
end stage of the disease (120 days), 57 genes were commonly
up-regulated (Fig. 3A; Supplementary Material, Table S1) and
11 down-regulated (Fig. 3B; Supplementary Material,
Table S1). Thus 69.5% (66/95) and 26.4% (14/53) of the
genes identified, respectively, as up-regulated and down-
regulated at the beginning of the symptoms (90 days)
remain elevated at the end stage of the disease.
Table 1. Comparison of genes differentially expressed in pre-symptomatic SOD1G93A motoneurons using microarrays
Affymetrix probe set ID GenBank Gene name Fold change
Up-regulated in SOD1G93A
1417256_at NM_008607 Matrix metalloproteinase 13 7.63
1440142_s_at BB750040 Mus musculus-transcribed sequences, ESTs 4.22
1437685_x_at BB235530 Fibromodulin 2.75
1415973_at BF141776 Myristoylated alanine-rich protein kinase C substrate 2.74
1437874_s_at AV225808 Hexosaminidase B 2.55
1416318_at AF426024 Serine (or cysteine) proteinase inhibitor, clade B, member 1a 2.30
1417868_a_at NM_022325 Cathepsin Z 2.26
1426852_x_at X96585 Nephroblastoma overexpressed gene 2.15
1421840_at BB305534 ATP-binding cassette, sub-family A (ABC1), member 1 2.15
1423537_at BB622036 Growth-associated protein 43 2.11
1432416_a_at AK005498 Nucleophosmin 1 1.91
1438118_x_at AV147875 Vimentin 1.80
1422860_at NM_024435 Neurotensin 1.72
1448595_a_at NM_009052 Reduced expression 3 1.67
1438945_x_at BB142324 Gap junction membrane channel protein alpha 1 1.61
1438940_x_at AV170171 High-mobility group nucleosomal-binding domain 1 1.60
1434449_at BB193413 Aquaporin 4 1.57
Down-regulated in SOD1G93A
1427351_s_at BB226392 Immunoglobulin heavy chain 6 23.30
1436944_x_at BB504983 Mus musculus-transcribed sequence 22.38
1439833_at BQ176645 Mus musculus adult male cortex cDNA 22.28
1416311_s_at NM_0094461 Tubulin, alpha 3 22.15
1423478_at BF660388 Protein kinase C 21.91
1441894_s_at BB071890 GRP1-associated scaffold protein 21.63
1437968_at AI385669 Glutamate receptor, ionotropic, NMDA1 (zeta 1) 21.62
1439368_a_at AV002797 Solute carrier family 9, isoform 3 regulator 2 21.56
1443824_s_at BB193643 Carbonic anhydrase 7 21.55
1433806_x_at AW324084 Calreticulin 21.53
1417606_a_at NM_007591 Calreticulin 21.52
List of genes whose transcripts were regulated by 1.5-fold or more (P, 0.05) in mutant mice. RNA was extracted from 2000–2400 microdissected
motoneurons issued from one animal. Three chips were analyzed for each condition (control and mutant). Gene expression levels were compared in
disease versus control animals. Fold change was calculated as the ratio between the average values of expression in mutant animals relative to the
average values of controls; in all comparisons, a positive value indicates a higher level of expression in mutant animals versus negative numbers
that show a higher level in controls.
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Genes de-regulated at an asymptomatic age are also
de-regulated at symptomatic ages
During disease progression in SOD1G93A motoneurons, we
monitored the expression of those genes that were shown to
be de-regulated at a pre-symptomatic age (60 days of age)
(see Table 1). The differential gene expression was validated
using real-time PCR (Table 3). Whereas vimentin was up-
regulated by only 1.80-fold at a pre-symptomatic age, it
increased even further at 90 days of age (8.96-fold by micro-
array; 4.27-fold by Q-PCR) and remained elevated at the end
stage of the disease (4.03-fold by microarray; 3.22-fold by
Q-PCR). Matrix metalloproteinase 13 was up-regulated 4-
fold at 60 and 90 days of age and increased sharply by
14-fold (6-fold by microarrays) at 120 days of age. The
NOV was up-regulated both at a pre-symptomatic age and at
end-stage disease but surprisingly was not confirmed as de-
regulated at 90 days of age by Q-PCR. The expression of con-
nexin 43 was moderately up-regulated at 60 and 90 days of
age whereas at 120 days, the expression level was similar to
that of the controls. GAP-43 showed a transitory elevation at
90 days of age and decreased slightly at the end stage of the
disease. For the down-regulated genes, ionotropic glutamate
receptor NMDA zeta 1 expression showed a 1.2-fold reduction
at 60 and 90 days of age (1.6-fold and 1.75, respectively, by
microarray) and a 2.3-fold (2.08-fold by microarray) reduction
at end stage of the disease.
Few cell-death-associated genes are de-regulated
in motoneurons during disease progression
To determine in which biological processes the de-regulated
genes may be involved, we queried the Gene Ontology data-
base (GO; http://www.geneontology.org/). At 90 and 120
days of age, up-regulated genes related to cell growth and/or
maintenance were significantly over-represented (P , 0.001)
(Table 4, Supplementary Material, Tables S2 and S3).
Indeed, 54 of the 95 (P ¼ 9.94  1026) genes up-regulated
in SOD1G93A motoneurons belonged to these biological
processes at 90 days of age; this enrichment increased
even further at 120 days of age with 211 of the 389
(P ¼ 3.744  10215) up-regulated genes corresponding to
this category. Furthermore, we identified de-regulated genes
that belong to other biological processes at the end stage
of the disease, e.g. 43 of the 389 up-regulated genes were
involved in developmental processes.
Table 2. Comparison of the fold changes observed at a pre-symptomatic age by microarrays versus real time PCR
GenBank Gene name Description Array Real-time PCR
Genes up-regulated in SOD1G93A
NM_008607 Mmp13 Matrix metalloproteinase 13 7.63 4.24+ 0.07
X96585 Nov Nephroblastoma overexpressed gene 2.15 3.34+ 0.17
AV147875 Vim Vimentin 1.80 1.79+ 0.02
BB142324 Gja1 Gap junction membrane channel protein
alpha 1 (connexin 43)
1.61 1.52+ 0.04
AV225808 Hexb Hexosaminidase B 2.55 Not confirmed
BB622036 Gap43 Growth associated protein 43 2.11 Not confirmed
NM_009052 Rex3 Reduced expression 3 1.67 Not confirmed
Genes down-regulated in SOD1G93A
AI385669 Grin1 Glutamate receptor, ionotropic, NMDA1 (zeta1) 21.62 21.18+ 0.1
To confirm the microarray results, eight genes were selected and analyzed by real-time PCR. For each sample, real-time PCR was done in triplicate.
Fold change corresponds to the ratio between the expression levels in mutant animals relative to controls; a positive value indicates a higher level of
expression in mutant animals versus a negative number that shows a higher level in controls.
Figure 3. Global mRNA changes in microdissected motoneurons during the
progression of the disease. Gene expression levels of laser-captured
SOD1G93A motoneurons in mutant versus control animals were compared at
three different stages of the disease (60, 90 and 120 days); 34 000 transcripts
were screened. (A) Up-regulated genes. We found nine genes up-regulated at
all stages of the disease (matrix metalloproteinase 13, vimentin, nephroblas-
toma overexpressed gene, serine proteinase inhibitor (clade B, member 1a),
growth-associated protein 43, aquaporin 4, mus musculus transcribed
sequences (BB750040), myristoylated alanine-rich protein kinase C substrate
and cathepsin Z). One gene showed an up-regulation at an asymptomatic age
(60 days) and early symptomatic age (90 days), 57 genes showed an up-
regulation at early and advanced stages (120 days) of the disease and four
genes were up-regulated at 60 and 120 days of age. We found three genes dif-
ferentially expressed uniquely at a pre-symptomatic age, 28 at an early symp-
tomatic stage and 319 at the end stage of the disease. (B) Down-regulated
genes. We found three genes down-regulated at all stages of the disease
(GRP1 (general receptor for phosphoinositides 1)-associated scaffold
protein, immunoglobulin heavy chain 6 and glutamate ionotropic receptor,
NMDA1). Eleven genes showed a down-regulation at early (90 days) and
advanced stages (120 days) of the disease and one gene was down-regulated
at 60 and 120 days of age. We found seven genes down-regulated uniquely
at a pre-symptomatic age, 39 at an early symptomatic stage and 38 at the
end stage of the disease.
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Out of the 696 genes associated with cell death present on
the mouse 430 2.0 chip, not a single gene was de-regulated
in SOD1G93A motoneurons during disease progression.
This is surprising because there is growing evidence in both
ALS patients and SOD1G93A mice that molecular components
of programmed cell death may be implicated in motoneuron
degeneration (for a review, see (9)). For this reason, we
examined the expression level by real-time PCR of certain
genes associated with cell death both in the entire spinal
cord (L2–L5) and in microdissected motoneurons; Q-PCR is
a more sensitive technique than microarray analysis.
The genes examined were caspase-1, -3, -7 and -9, XIAP
(X-linked inhibitor of apoptosis protein), Bax and TNFa
(tumor necrosis factor a). At an early symptomatic age (90
days of age), two genes were de-regulated in the entire
spinal cord; caspase-9 expression was down-regulated and
TNFa level showed a 2-fold increase. In isolated motoneur-
ons, only caspase-1 was up-regulated at this same age
(Table 5).
At the end stage of the disease (120 days of age), all of the
selected genes, except caspase-9 and XIAP, showed an
increased expression in the entire spinal cord of SOD1G93A
mice and there was a pronounced increase in TNFa (5.5-
fold). In opposition, in pure motoneurons only caspase-1 and
-3 were modestly up-regulated and XIAP levels (not present
on the Affymetrix array) decreased by 1.9-fold (Table 5).
The expression levels of caspase-1, -3 and XIAP were 2-,
4- and 60-fold lower, respectively, in purified motoneurons
when compared with lumbar spinal cord. Therefore, the true
expression level of caspase-1, caspase-3 and XIAP was very
low in isolated motoneurons when compared with the entire
spinal cord. Taken together, these results suggest either that
death signals arise mainly from other cell types and/or that
motoneurons that we had selected are at an early stage of
the cell death process.
A small increase in the level of glial fibrillary acidic protein
(GFAP) expression was observed in motoneuron samples from
mutant mice during disease progression. At a pre-symptomatic
age (60 days), GFAP was not detected in control and mutant
motoneurons; at post-symptomatic ages (90 and 120 days),
GFAP levels were not different from the background value
in controls but a low level of expression was detected in
samples from the mutants. During disease progression, moto-
neurons undergo neurodegeneration and become atrophic
(Fig. 1H); thus there is an increased risk of microdissecting
unwanted material surrounding motoneurons such as
astrocytes.
Vimentin is expressed in the cytoplasm of motoneurons
and formed inclusions during the progression of the
disease
The gene profile of microdissected motoneurons in two other
mouse models that develop an inherited motoneuron degener-
ation (progressive motor neuronopathy and wobbler) also
showed an up-regulation of the vimentin gene at a pre-
symptomatic age (data not shown). Therefore, our goal was
to determine whether vimentin was expressed by postnatal
motoneurons and to follow its expression during the pro-
gression of the disease.
Using in situ hybridization, we showed mRNA expression
of vimentin in motoneurons (cytoplasm and nucleus) and
less intensely in other cells in the gray matter of the spinal
cord in both control and mutant animals during disease pro-
gression (Fig. 4). We observed a more intense signal in the
motoneurons of the SOD1G93A mice at 120 days of age
Table 3. Genes de-regulated at a pre-symptomatic age remain elevated at a symptomatic age
GenBank Gene name Description Days Array Real-time PCR
AV147875 Vim Vimentin 60 1.80 1.79+ 0.02
90 8.96 4.27+ 0.14
120 4.03 3.22+ 0.26
NM_008607 Mmp13 Matrix metalloproteinase 13 60 7.63 4.24+ 0.07
90 2.74 3.21+ 0.16
120 6.17 13.90+ 0.9
X96585 Nov Nephroblastoma overexpressed gene 60 2.15 3.34+ 0.17
90 4.59 21.07+ 0.55
120 3.73 5.01+ 0.49
BB142324 Gja1 Gap junction membrane channel protein alpha 1
(connexin 43)
60 1.61 1.52+ 0.04
90 1.34 1.52+ 0.33
120 1.44 21.05+ 0.33
BB622036 Gap43 Growth-associated protein 43 60 2.11 21.14+ 0.15
90 4.04 2.80+ 0.18
120 3.32 1.43+ 0.13
AI385669 Grin1 Glutamate receptor, ionotropic, NMDA1 (zeta 1) 60 21.62 21.18+ 0.1
90 21.75 21.20+ 0.05
120 22.08 22.32+ 0.07
We followed the differential expression of a selected group of genes that were de-regulated in SOD1G93A mice at a pre-symptomatic age. These genes
were analyzed at 90 (onset of disease) and 120 days of age (end stage of disease). Three chips were analyzed for each condition (control and mutant) at
all time points. Real-time PCR analyses were done in triplicate for each sample. Fold change indicates the ratio between the expression levels in mutant
animals relative to controls; positive values indicate a higher level of expression in mutant animals versus negative numbers that show a higher level in
controls.
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(Fig. 4D). In addition, the spinal cord tissue from the mutant
mice was consistently more fragile at the late stage of the
disease. Using an immunohistochemical approach, we
studied the localization of vimentin in control and mutant
animals at different ages. In control and SOD1G93A mice at
60 days of age, a weak staining of vimentin was observed in
the cytoplasm of motoneurons (Fig. 5A and D). Diffuse
vimentin staining with occasional inclusions (Fig. 5A,
arrow) was detected in control animals, whereas inclusions
were more frequent in SOD1G93A motoneurons (Fig. 5D,
arrow). At the end stage of the disease (i.e. 120-day-old),
the overall expression of vimentin was increased in the cyto-
plasm of motoneurons as well as in other cells in the gray
matter of control and mutant animals (Fig. 5G and J). Abun-
dant vimentin inclusions were seen in the cytoplasm of the
mutants at this later age (Fig. 5J, arrows). Furthermore,
using double-label immunohistochemical staining, we
showed that vimentin and neurofilament heavy chains (phos-
phorylated and non-phosphorylated forms) were localized in
the same motoneurons as well as in other cell types
(Fig. 5C, F, I and L).
DISCUSSION
In this study, we have characterized the ‘molecular signature’
of a pure SOD1G93A motoneuron subpopulation during disease
progression. By using a combination of LCM and high-density
cDNA microarrays, we screened a large number of transcripts
(34 000) and identified significant differential expression in
SOD1G93A-mutated motoneurons compared with control
motoneurons from a pre-symptomatic age to the end stage
of the disease. Unexpectedly, we observed no widespread
induction of cell death genes in motoneurons of mutated
SOD1G93A mice. In addition, an immunohistochemical analy-
sis has shown that the intermediate filament, vimentin, forms
inclusions in spinal cord motoneurons during disease pro-
gression in a mouse model of ALS.
Few genes are de-regulated at an asymptomatic age
At a pre-symptomatic age (60 days of age), only 0.08% of the
tested genes (27/34 000) are de-regulated in pure motoneur-
ons. As the analysis is done before the onset of the symptoms,
differential molecular expression might reflect events that
either initiate the disease or reflect an early protective response
of the targeted cells.
Among these de-regulated genes, more than 50% remain
differentially expressed during disease progression. Matrix
metalloproteinase 13 (MMP-13) gene is highly up-regulated
at both asymptomatic and symptomatic stages; it belongs to
a family of enzymes that are the main mediators of extracellu-
lar matrix degradation (10). Even though substrates of MMPs
in the CNS are unknown, an excessive production of MMP
may not only be toxic but also involved in neuroinflammation
(for review, see (11)). Furthermore, MMP-9 is increased in the
motor cortex and spinal cord motoneurons of ALS patients
(12). Thus MMP-13 may be involved in motoneuron degener-
ation at an early stage.
The gene for vimentin, an intermediate filament type III, is
up-regulated at a pre-symptomatic age in SOD1G93A moto-
neurons and also in motoneurons from two other mouse
models of motoneuron degeneration (progressive motor neuro-
nopathy and wobbler; data not shown). In striking opposition,
no deregulation is observed in the entire spinal cord of mutant
mice at the same age. In situ hybridization during the
progression of the disease confirms the presence of vimentin
Table 4. Classification of over-represented genes obtained by microarrays in motoneurons of SOD1G93A mice during the disease progression using the gene ontol-
ogy database (http://www.geneontology.org/)
Up-regulated genes Total P 90 P 120
Classification Found P-value Found P-value
Cell growth and/or maintenance 54 9.91E-6 211 3,74E-15
Cell organization and biogenesis 12 1.47E-2 63 3.33E-15
Cytoskeleton organization and biogenesis 1335 6 6.31E-2 42 7.34E-13
Cytoplasm organization and biogenesis 2804 12 1.47E-2 63 3.33E-12
Metabolism 42 1.29E-4 152 2.68E-8
Electron transport 4575 17 1.45E-2 67 1.21E-5
Lipid metabolism 1301 6 5.71E-2 23 1.06E-3
Coenzymes and prosthetic group metabolism 1067 19 2.60E-3
Protein biosynthesis 1070 7 7.54E-3 19 2.68E-3
Energy pathways 1709 8 2.79E-2 26 4.06E-3
Biosynthesis 1291 9 1.63E-3 20 9.17E-3
Carbohydrate metabolism 1808 11 1.48E-3 24 2.55E-2
Catabolism 519 5 4.91E-3 9 3.76E-2
Cell growth 50 2.50E-7
Cell homeostasis 3 1.66E-3 7 5.00E-5
Transport 13 2.21E-2 45 1.89E-3
Ion transport 3028 13 1.09E-2 45 2.79E-4
Development 43 4.93E-11
Cell differentiation 1589 43 4.93E-11
Certain genes were de-regulated by at least 1.5-fold in motoneurons of SOD1G93A mice at an early symptomatic age (90 days of age) and at the end
stage of the disease (120 days of age). The table provides the total number of genes with that particular gene ontology term on the Affymetrix Gene-
Chipw MOE 430 2.0.
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within motoneurons. These findings strongly support a specific
up-regulation of vimentin within the affected cells in moto-
neuron disease. Vimentin is prominently expressed in glial
cells (13) but also in neurons during early development
(14–16). It has been suggested to play a role in the early gen-
eration and extension of neurites following injury (17,18) as
well as in enabling retrograde transport of activated MAP
kinases in sensory axons following injury (19). During
disease progression, the mRNA expression of vimentin is
increased even further in SOD1G93A motoneurons at an early
symptomatic age (90 days) and remains elevated at the end
stage of the disease (120 days). Using immunohistochemistry,
we show that vimentin inclusions are present in the cytoplasm
of pre-symptomatic SOD1G93A mutants and become more
abundant at the end stage of the disease.
Prominent cytoplasmic inclusions or aggregates are a hall-
mark of several neurodegenerative disorders (for review, see
(20–23)). In ALS patients and SOD1 mutant mice, protein
aggregates such as bunina bodies and ubiquitinated/SOD
inclusions have been reported (for review, see (24)). It
remains controversial whether the presence of inclusions,
actually triggers motoneuron death, results from a cell death,
process or reflects a cellular protective mechanism (for
review, see (1,20–22)). Formation of aggresomes has been
postulated to be a protective cellular response to overloading
the proteasome in HEK293 cells transfected with mutated
forms of SOD1 (25). A hallmark of aggresomes is the depo-
sition of intermediate filament proteins such as vimentin;
most aggresomes are delivered to the microtubule-organizing
center where they are surrounded by a vimentin ‘cage’
(20,25,26).
An increase in IGFBPs has been reported in ALS patients
(27). One member of this family, NOV, is up-regulated in
SOD1G93A motoneurons at all stages of the disease and
binds both IGF-1 and IGF-2 (28). IGF-1 is a potent survival
factor for motoneurons and viral delivery of IGF-1 has been
shown to prolong survival of SOD1G93A mice (29). Thus, an
increase of IGFBPs might diminish the availability of IGF-1
and lead to motoneuron death by forming heterodimeric IGF
complexes.
At a symptomatic age, few cell-death-associated genes are
de-regulated whereas a massive de-regulation of genes
associated with cell growth and maintenance is observed
The number of differentially expressed genes remains rela-
tively low even at a symptomatic age. Indeed, 0.28 and
1.14% of the tested genes are up-regulated at an early sympto-
matic age and at the end stage of the disease, respectively;
down-regulated genes correspond to 0.16% at both ages.
This small number of de-regulated genes is in agreement
with a recent study using human spinal motoneurons in spora-
dic ALS where 1% of the 4845 tested genes were up-regulated
and 3% down-regulated (2). In contrast to Jiang et al. (2), we
do not find a significant de-regulation of genes involved in
apoptotic pathways but a massive up-regulation of genes
involved in cell growth and/or maintenance. Differences in
gene expression seen between ALS patients and SOD1G93A
motoneurons (a mouse model for familial ALS) may be due
to differences in sporadic versus familial ALS, post-mortem
delay modifications in human tissue, stage of the disease and
the composition and the number of genes examined on the
arrays.
Other workers have reported an activation of apoptotic
genes in the entire spinal cord of ALS patients and SOD1
mice (for review, see (1,30)). Because of the heterogeneous
population of cells in the spinal cord, it is not surprising to
find transcriptional differences compared to pure motoneur-
ons. In our study, 696 genes involved in cell death pathways
were examined by microarrays and none of those genes are
de-regulated. The two main cell death pathways (i.e. Bcl-2
and caspase family) suggested to be implicated in the ALS
neurodegenerative process (9) are largely queried among
these 696 tested genes. Molecular events that initiate the
death of motoneurons in ALS patients or in SOD1 mouse
models remain elusive. At symptomatic ages, massive micro-
glia activation, astrogliosis and T-cell infiltration (9,31) have
been reported in SOD1-mutated mice. These non-neuronal
cells may release extracellular inflammatory factors and
mediators of programmed cell death that induce or amplify
cell death signals in motoneurons.
Table 5. Comparison of the fold changes of genes involved in apoptotic and inflammatory pathways observed in entire spinal cord segments versus microdissected
motoneurons using real-time PCR
Description Entire spinal cord Motoneurons
Fold P 90 Fold P 120 Fold P 90 Fold P 120
Bax 1.02+ 0.047 1.36+ 0.082 21.23+ 0.043 1.19+ 0.11
Caspase 1 1.06+ 0.06 1.81+ 0.21 1.76+ 0.28 1.59+ 0.24
Caspase 3 1.09+ 0.06 1.41+ 0.2 21.09+ 0.23 2.45+ 0.55
Caspase 7 1.02+ 0.12 2.12+ 0.22 Too low to determinea Too low to determinea
Caspase 9 21.25+ 0.11 21.2+ 0.11 Too low to determinea Too low to determinea
XIAP 21.08+ 0.05 21.05+ 0.06 21.06+ 0.34 21.89+ 0.30
TNF alpha 2.05+ 0.34 5.49+ 0.6 Too low to determinea Too low to determinea
To confirm the specificity of the differential expression within motoneurons, we selected genes involved in the apoptotic pathway and undertook real-
time PCR on the entire L2–L5 spinal cord segments. For each sample, real-time PCR was done in triplicate. Fold change represents the ratio between
the expression levels in mutant animals relative to controls; positive values indicate a higher level of expression in mutant animals versus negative
numbers that show a higher level in controls.
aThe expression level in control and mutant animals was too low to determine a fold change.
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A temporal activation of caspase-1 and -3 has been reported
in motoneurons and in non-neuronal cells of SOD1G93A mice;
activation of caspase-3 in motoneurons is contemporaneous of
cell death which is in contrast to activation of caspase-1 that
occurs at an earlier stage of the disease (32–34). We do not
find an up-regulation of either caspase-1 and-3 mRNAs by
microarray analysis but in agreement with the previous
studies we find a modest temporal increase using Q-PCR.
Such a discrepancy could result from the inability of the
microarray analysis to detect low abundance transcripts. It
had been hypothesized that caspase activation within moto-
neurons could result from diffusible factors emanating from
neighboring cells (32). Furthermore, it had been shown that
SOD1 toxicity is required in both motoneurons and in non-
neuronal cells to induce cell death (8); indeed expression of
the mutated form of SOD1 in either neurons (6,7) or astrocytes
(5) alone does not cause motoneuron degeneration. Normal
non-neuronal cells protect motoneurons that express the
mutated form of SOD1 when present in sufficient number
whereas an SOD1 mutation in non-neuronal cells induces
degeneration in neighboring normal motoneurons (8). We
cannot exclude an intrinsic activation of cell death pathways
(mitochondrial pathway and/or ER pathway (1,35)) but taken
together, our results are compatible with an extrinsic acti-
vation (such as a death receptor pathway (1,35)) of pro-
grammed cell death where neighboring cells might trigger
motoneuron death.
Motoneuron death may also reflect a balance between pro-
tective and toxic gene products (30,36,37). For example, a
balance between the antiapoptotic molecule XIAP and the
inhibitor XAF1 plays a role in the differential sensitivity to
death of motoneurons after axotomy (36,37); thioredoxin
promotes cell survival and is up-regulated in ALS patients
(38). An up-regulation of 14-3-3 proteins involved in
preventing apoptosis (39) is also observed in ALS tissue
(40). Up-regulation of genes involved in cell growth and/or
maintenance may reflect a transitory neuroprotective pheno-
menon. Indeed, motoneuron loss is not synchronized and
occurs over a long period of time. Despite the low number
of motoneurons at 120 days of age, we microdissected a sub-
population of motoneurons that had a diameter of at least
25 mm and an identifiable nucleus; these criteria are necessary
to exclude the possibility of dissecting interneurons or even
gamma-motoneurons that are smaller. Motoneurons that we
analyzed may be at an early stage of the cell death process
and may still be capable of resisting degeneration. These
motoneurons might have an intrinsic but transient ability to
up-regulate protective gene products in response to the
expression of mutant SOD1.
In conclusion, by combining LCM and microarrays, we
demonstrate alterations in gene expression profiles during
disease progression in SOD1G93A motoneurons. One gene,
coding for vimentin, was up-regulated at all three ages
examined and the vimentin protein forms inclusions during
Figure 5. Immunostaining of vimentin and neurofilaments in lumbar spinal
cord sections from control and SOD1G93A mice during the progression of
the disease. (A–C) Photographs of the lumbar (L2–L5) spinal cord in a
60-day-old control littermate, (D–F) 60-day-old SOD1G93A mouse (pre-
symptomatic age), (G–I) 120-day-old control littermate and (J–L) 120-
day-old SOD1G93A mouse (end stage of disease). Immunostaining with a
polyclonal antibody to vimentin (A, D, G and J), a monoclonal antibody to
neurofilaments (B, E, H and K) and a merged image of vimentin and neurofila-
ments (C, F, I and L). Note that in all cases vimentin and neurofilaments are
located in the same motoneurons; in transgenic animals (D–F and J–L), moto-
neurons show characteristics of degeneration and atrophy along with vimentin
inclusions in the cytoplasm. Scale bar represents 20 mm.
Figure 4. In situ hybridization of vimentin in lumbar spinal cord sections from
control and SOD1G93A mice during the progression of the disease. (A and B)
mRNA expression of vimentin in lumbar (L2–L5) spinal cord in 90-day-old
control and SOD1G93A mice (early symptomatic age). (C and D) Hundred
and twenty-day-old control and SOD1G93A mice (end stage of the disease).
In all cases, vimentin mRNA is expressed in the cytoplasm and the nucleus
of motoneurons and less abundantly in other cell types of the gray matter.
(A and C) Control mice. (B and D) Mutant mice. Scale bar represents 20 mm.
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progression of the disease. At symptomatic ages, we do not
find a significant de-regulation of genes involved in cell
death but a massive up-regulation of genes involved in cell
growth and maintenance. In ALS, it remains to be determined
whether the origin of the disease is in the motoneurons or in
non-neuronal cells. As our results are compatible with a
non-cell autonomous toxicity of mutated SOD1, a high pri-
ority will be to analyze gene profiles of non-neuronal cells
such as astrocytes.
MATERIALS AND METHODS
Animal models
Transgenic mice overexpressing human SOD1 carrying the
G93A mutation (strain designation: B6SJL-Tg(SOD1-
G93A)1Gur) were purchased from the Jackson Laboratory
(Bar Harbour, ME, USA). Transgenic progeny were identified
by polymerase chain reaction (PCR) for human SOD1; non-
transgenic littermates served as controls. Only males were
used. Pre-symptomatic mice (60-day-old) were used to ident-
ify early modifications in gene expression; the progression of
the disease was examined in early symptomatic (90-day-old)
and end stage of the disease (120-day-old). Animals were
sacrificed by decapitation. The experimental procedures
were approved by the Ethical Committee for Animal Exper-
imentation of the Geneva Veterinary Office.
LCM of motoneurons
Spinal cords (lumbar regions L2–L5) were rapidly removed,
embedded in Tissue-Tek OCT Compound (Zoeterwoude,
The Netherlands), placed at 2208C for 1 h and then stored
at 2808C. Tissues were sectioned at 16 mm and mounted on
PALMw PEN-covered membrane slides (PALM AG, Bern-
ried, Germany). LCM was performed immediately after sec-
tioning. To identify motoneurons, a light staining in 0.1%
methylene blue was done for 1 min; the sections were then
dehydrated in graded solutions of ethanol (70, 95 and 100%)
for 10 s each. Once air-dried, motoneurons were microdis-
sected using the Palm Robot-Microbeam system (PALM
AG, Bernried, Germany). Criteria for motoneuron selection
include a diameter of greater than 25–30 mm and an identifi-
able nucleus. Motoneurons were catapulted into a microfuge
cap moistened with a drop of mineral oil (Sigma, Saint
Louis, Missouri). Approximately 100 cells were collected
per cap. A total of 2000–2400 cells were used for analysis
on one GeneChip array. Motoneurons were pooled from one
animal per GeneChip. Additionally, we collected 900–1200
motoneurons from three mice for subsequent quantitative
real-time PCR analysis.
RNA extraction and quality test
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Maryland, USA) including DNase treatment (on columns) to
remove potential genomic DNA contamination. We tested
the quality of the starting RNA (Agilent 2100 bioanalyzer,
RNA 6000 Pico LabChip, Palo Alto, USA) and proceeded
only if the quality was satisfactory. Criteria were the
absence of degradation of the ribosomal RNA that represents
90–95% of total RNA and a ratio 28S/18S equal to 1.8–2.0.
cRNA quality was also tested after both amplifications using
RNA 6000 Nano LabChip (Agilent 2100 bioanalyzer, Palo
Alto, USA).
cRNA preparation, oligonucleotide microarray
hybridization and analysis
Hybridization targets were obtained following a double ampli-
fication procedure according to the protocol developed by
Affymetrix (GeneChipw Eukaryotic Small Sample Target
Labeling Assay Version II, Affymetrix, Santa Clara, USA).
A hybridization mixture containing 5.5 mg of biotinylated
cRNA was generated. The biotinylated cRNA was hybridized
to Affymetrix GeneChipw MOE 430 2.0. Three chips were
hybridized, each corresponding to one mouse, for each con-
dition. Chips were visualized on an Scs 3000 gene scanner
(Affymetrix, Santa Clara, USA) and image files analyzed.
We selected the differentially expressed transcripts using the
Affymetrix software MAS 5.0 and carried out pair-wise com-
parison analyses where each of the mutant samples was com-
pared with each of their respective control samples. This
analysis is based on the Mann–Whitney pair-wise comparison
test and allows the ranking of the results by concordance as
well as the calculation of significance (P-value) of each ident-
ified gene (41,42). A gene must exhibit 50% or more of
‘present’ calls in all samples to be considered ‘expressed’
and has two or more present calls among the three sets of
samples. Fold differences were calculated as the ratio
between the average values within each condition. Signal
values and detection calls (present or absent) for all samples
were determined by using Affymetrix MAS5.0. To identify
transcripts that are differentially expressed between the con-
trols and the mutant mice, we defined a criterion of a 1.5-
fold and greater difference plus a P-value of ,0.05.
Determination of over-representation of gene ontology
terms during disease progression in SOD1G93A
motoneurons
Data were analyzed with Microarray Analysis GCOS 1.2
(Affymetrix) and classified according to GeneOntology
terms (http://www.geneontology.org/) using GeneSpring soft-
ware (version 7.0, Silicon Genetics, Redwood City, CA). Gene-
Ontology allows the classification of a gene according to its
molecular function, biological process, cellular component
and chromosomal localization. Genes with each of these func-
tional annotations were assessed to see if they were over-
represented in motoneurons of SOD1G93A mice during the
progression of the disease. If the P-value of observed genes
in motoneurons with a particular gene ontology term was
,0.001, the gene was considered to be significantly over-
represented.
Quantitative real-time PCR
Total RNA from 900–1200 microdissected motoneurons was
extracted as described earlier and used as a template in real-
time PCR. Three animals were used for each analysis. One
3318 Human Molecular Genetics, 2005, Vol. 14, No. 21
round of amplification was done following the first cycle (first
cDNA and cRNA synthesis) of the Affymetrix double ampli-
fication procedure before undertaking reverse transcription
with random hexamers (Superscript II, Invitrogen, Carlsbad,
CA). Real-time PCR using Syber Green PCR Master Mix
and Abi Prism SDS 7900 HT (Applied Biosystems, Foster
City, CA) was done according to the manufacturer’s protocol.
All amplicons were designed within the 30 end of the cDNA
using Primer Express Software 2.0 (Applied Biosystems)
and when possible, overlapped exon–exon junctions. Total
RNA from the L2–L5 spinal cord segment was extracted as
previously described and used as a template as described
earlier but without an amplification step (for the sequences
of the primers, see Supplementary Materials, Table S4). All
samples were analyzed in triplicate and the values normalized
to two reference genes GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) and RPS9 (mitochondrial ribosomal protein
S9) (43).
Histology and morphometry
Sixty- and 120-day-old mice (controls and SOD1G93A) mice
were killed with an overdose of pentobarbital (Nembutal,
Narconen, Switzerland) and perfused transcardially with 4%
paraformaldehyde in PBS. The lumbar spinal cords were
removed, post-fixed and processed for paraffin embedding.
Sections (8 mm) were stained with cresyl violet and then
mounted in Eukitt. Lumbar spinal cords from 60-, 90- and
120-day-old mice (controls and SOD1G93A) were embedded
in Tissue-Tek OCT Compound (Zoeterwoude), sectioned at
16 mm and stained with cresyl violet. Motoneurons were
classified into two categories (diameter of greater than 25–
30 mm and an identifiable nucleus and diameter lower than
25 mm) using the Palm Robot-Microbeam system (PALM
AG). Each control and mutant group includes two and three
animals, respectively. For each animal, at least 300 motoneur-
ons were classified.
In situ hybridization
Lumbar spinal cords from 90- and 120-day-old mice (controls
and SOD1G93A) were embedded in Tissue-Tek OCT Com-
pound (Zoeterwoude), sectioned at 10 mm and mounted on
gelatin-coated slides. In situ hybridization was done using a
vimentin-specific FITC-labeled Custom Design TriSeq kit
according to the manufacturer’s instructions (Biognostik,
Go¨ttingen, Germany). Sections were hybridized with vimen-
tin, poly-dT, b-actin, a-tubulin or random (negative) control
probes (20 U/ml); mRNA expression was revealed with alka-
line phosphatase-conjugated anti-FITC antibody and visual-
ized with AEC+ Substrate Chromogen (both from
DakoCytomation AG, Postfach, Switzerland). Each group
includes at least two animals.
Double labeling immunofluorescence
Sixty- and 120-day-old mice were perfused and embedded in
Tissue-Tek OCT compound as previously described. Twelve-
micrometer sections of the lumbar spinal cord were mounted
on slides and washed in PBS for 5 min. To prevent non-specific
antibody binding, sections were treated for 30 min in PBS-
containing lysine (20 mM, pH 7.4). Tissue sections were then
permeabilized and blocked for 30 min with PBS-containing
fetal bovine serum (FBS) (10%) and Triton X-100 (0.4%).
Goat polyclonal anti-vimentin and mouse monoclonal
anti-neurofilament 200 (both Sigma) primary antibodies were
used in combination at 1:100 and 1:400, respectively. They
were diluted in the blocking solution and sections were incu-
bated overnight at 48C. After three washes with PBS and 1 h
in the blocking solution (FCS in PBS), sections were incubated
with a combination of the secondary antibodies Alexa 594
donkey anti-goat IgG and Alexa 488 goat anti-mouse IgG
(both 1:1500, Molecular Probes, Eugene, OR) for 45 min at
room temperature. The sections were coverslipped using
Fluorosave (Calbiochem, La Jolla, CA) and analyzed with a
Zeiss Microscope equipped with a digital camera (Axiocam,
Carl Zeiss, Oberkochen, Germany). The controls were done
in the absence of the primary antibody and were negative in
all cases. Each group includes at least three animals.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
We thank Gisele Gillieron, Beatrice King and Didier Chollet
for excellent technical help and Marcel Ferrer-Alcon,
Yannick Simonin and Temugin Berta for reading the manu-
script. All microarrays and real-time PCR experiments were
done in the Genomics Platform, National Center of Compe-
tence in Research ‘Frontiers in Genetics’, University of
Geneva, Switzerland. This work was supported by the Associ-
ation Franc¸aise Contre les Myopathies (France), the Carlos
and Elsie de Reuter Foundation (Switzerland), the Foundation
Boninchi (University of Geneva), the Institut International de
Recherche en Paraple´gie and the Swiss National Foundation.
Conflict of Interest statement: No conflict of interest.
REFERENCES
1. Bruijn, L.I., Miller, T.M. and Cleveland, D.W. (2004) Unraveling the
mechanisms involved in motor neuron degeneration in ALS. Annu. Rev.
Neurosci., 27, 723–749.
2. Jiang, Y.M., Yamamoto, M., Kobayashi, Y., Yoshihara, T., Liang, Y.,
Terao, S., Takeuchi, H., Ishigaki, S., Katsuno, M., Adachi, H. et al. (2005)
Gene expression profile of spinal motor neurons in sporadic amyotrophic
lateral sclerosis. Ann. Neurol., 57, 236–251.
3. Olsen, M.K., Roberds, S.L., Ellbrock, B.R., Fleck, T.J., McKinley, D.K.
and Gurney, M.E. (2004) Disease mechanisms revealed by transcription
profiling in SOD1-G93A transgenic mouse spinal cord. Ann. Neurol., 50,
730–740.
4. Yoshihara, T., Ishigaki, S., Yamamoto, M., Liang, Y., Niwa, J.,
Takeuchi, H., Doyu, M. and Sobue, G. (2002) Differential expression of
inflammation- and apoptosis-related genes in spinal cords of a mutant
SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
J. Neurochem., 80, 158–167.
5. Gong, Y.H., Parsadanian, A.S., Andreeva, A., Snider, W.D. and
Elliott, J.L. (2000) Restricted expression of G86R Cu/Zn superoxide
dismutase in astrocytes results in astrocytosis but does not cause
motoneuron degeneration. J. Neurosci., 20, 660–665.
Human Molecular Genetics, 2005, Vol. 14, No. 21 3319
6. Lino, M.M., Schneider, C. and Caroni, P. (2002) Accumulation of SOD1
mutants in postnatal motoneurons does not cause motoneuron pathology
or motoneuron disease. J. Neurosci., 22, 4825–4832.
7. Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. and
Rouleau, G.A. (2001) Neuron-specific expression of mutant superoxide
dismutase 1 in transgenic mice does not lead to motor impairment.
J. Neurosci., 21, 3369–3374.
8. Clement, A.M., Nguyen, M.D., Roberts, E.A., Garcia, M.L., Boillee, S.,
Rule, M., McMahon, A.P., Doucette, W., Siwek, D., Ferrante, R.J. et al.
(2003) Wild-type nonneuronal cells extend survival of SOD1 mutant
motor neurons in ALS mice. Science, 302, 113–117.
9. Przedborski, S. (2004) Programmed cell death in amyotrophic lateral
sclerosis: a mechanism of pathogenic and therapeutic importance.
Neurologist, 10, 1–7.
10. Nagase, H. and Woessner, J.F., Jr (1999) Matrix metalloproteinases.
J. Biol. Chem., 274, 21491–21494.
11. Yong, V.W., Power, C., Forsyth, P. and Edwards, D.R. (2001)
Metalloproteinases in biology and pathology of the nervous system. Nat.
Rev. Neurosci., 2, 502–511.
12. Lim, G.P., Backstrom, J.R., Cullen, M.J., Miller, C.A., Atkinson, R.D. and
Tokes, Z.A. (1996) Matrix metalloproteinases in the neocortex and spinal
cord of amyotrophic lateral sclerosis patients. J. Neurochem., 67,
251–259.
13. Menet, V., Prieto, M., Privat, A. and Ribotta, M. (2003) Axonal plasticity
and functional recovery after spinal cord injury in mice deficient in both
glial fibrillary acidic protein and vimentin genes. Proc. Natl Acad. Sci.
USA, 100, 8999–9004.
14. Cochard, P. and Paulin, D. (1984) Initial expression of neurofilaments and
vimentin in the central and peripheral nervous system of the mouse
embryo in vivo. J. Neurosci., 4, 2080–2094.
15. Tapscott, S.J., Bennett, G.S., Toyama, Y., Kleinbart, F. and Holtzer, H.
(1981) Intermediate filament proteins in the developing chick spinal cord.
Dev. Biol., 86, 40–54.
16. Fliegner, K.H., Kaplan, M.P., Wood, T.L., Pintar, J.E. and Liem, R.K.
(1994) Expression of the gene for the neuronal intermediate filament
protein alpha-internexin coincides with the onset of neuronal
differentiation in the developing rat nervous system. J. Comp. Neurol.,
342, 161–173.
17. Boyne, L.J., Fischer, I. and Shea, T.B. (1996) Role of vimentin in early
stages of neuritogenesis in cultured hippocampal neurons. Int. J. Dev.
Neurosci., 14, 739–748.
18. Dubey, M., Hoda, S., Chan, W.K., Pimenta, A., Ortiz, D.D. and Shea, T.B.
(2004) Reexpression of vimentin in differentiated neuroblastoma cells
enhances elongation of axonal neurites. J. Neurosci. Res., 78, 245–249.
19. Perlson, E., Hanz, S., Ben Yaakov, K., Segal-Ruder, Y., Seger, R., and
Fainzilber, M. (2005) Vimentin-dependent spatial translocation of an
activated MAP kinase in injured nerve. Neuron, 45, 715–726.
20. Ardley, H.C., Hung, C.C. and Robinson, P.A. (2005) The aggravating role
of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett.,
579, 571–576.
21. Caughey, B. and Lansbury, P.T. (2003) Protofibrils, pores, fibrils, and
neurodegeneration: separating the responsible protein aggregates from the
innocent bystanders. Annu. Rev. Neurosci., 26, 267–298.
22. Soto, C. (2003) Unfolding the role of protein misfolding in
neurodegenerative diseases. Nat. Rev. Neurosci., 4, 49–60.
23. Taylor, D.M., Minotti, S., Agar, J.N. and Durham, H.D. (2004)
Overexpression of metallothionein protects cultured motor neurons
against oxidative stress, but not mutant Cu/Zn-superoxide dismutase
toxicity. NeuroToxicology, 25, 779–792.
24. Wood, J.D., Beaujeux, T.P. and Shaw, P.J. (2003) Protein aggregation in
motor neurone disorders. Neuropathol. Appl. Neurobiol., 29, 529–545.
25. Johnston, J.A., Dalton, M.J., Gurney, M.E. and Kopito, R.R. (2000)
Formation of high molecular weight complexes of mutant Cu,
Zn-superoxide dismutase in a mouse model for familial amyotrophic
lateral sclerosis. Proc. Natl Acad. Sci. USA, 97, 12571–12576.
26. Johnston, J.A., Ward, C.L. and Kopito, R.R. (1998) Aggresomes: a
cellular response to misfolded proteins. J. Cell Biol., 143, 1883–1898.
27. Wilczak, N., de Vos, R.A. and De Keyser, J. (2003) Free insulin-like
growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor
neurons in amyotrophic lateral sclerosis. Lancet, 361, 1007–1011.
28. Christine, P.B., Wilson, E.M., Hwa, V., Oh, Y. and Rosenfeld, R.G.
(1999) Binding properties and distribution of insulin-like growth factor
binding protein-related protein 3 (IGFBP-rP3/NovH), an additional
member of the IGFBP superfamily. J. Clin. Endocrinol. Metab, 84,
1096–1103.
29. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D. and Gage, F.H. (2003)
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS
model. Science, 301, 839–842.
30. Malaspina, A. and de Belleroche, J. (2004) Spinal cord molecular
profiling provides a better understanding of amyotrophic lateral sclerosis
pathogenesis. Brain Res. Rev., 45, 213–229.
31. Alexianu, M.E., Kozovska, M. and Appel, S.H. (2001) Immune reactivity
in a mouse model of familial ALS correlates with disease progression.
Neurology, 57, 1282–1289.
32. Li, M., Ona, V.O., Gan, C., Chen, M., Jackson-Lewis, V., Andrews, L.J.,
Olszewski, A.J., Stieg, P.E., Lee, J.P., Przedborski, S. and Friedlander,
R.M. (2000) Functional role of caspase-1 and caspase-3 in an ALS
transgenic mouse model. Science, 288, 335–339.
33. Pasinelli, P., Houseweart, M.K., Brown, R.H., Jr and Cleveland, D.W.
(2000) Caspase-1 and -3 are sequentially activated in motor neuron death
in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral
sclerosis. PNAS, 97, 13901–13906.
34. Vukosavic, S., Stefanis, L., Jackson-Lewis, V., Guegan, C., Romero, N.,
Chen, C., Dubois-Dauphin, M. and Przedborski, S. (2000) Delaying
caspase activation by Bcl-2: a clue to disease retardation in a transgenic
mouse model of amyotrophic lateral sclerosis. J. Neurosci., 20,
9119–9125.
35. Vila, M. and Przedborski, S. (2003) Targeting programmed cell death in
neurodegenerative diseases. Nat. Rev. Neurosci., 4, 365–375.
36. Perrelet, D., Ferri, A., MacKenzie, A.E., Smith, G.M., Korneluk, R.G.,
Liston, P., Sagot, Y., Terrado, J., Monnier, D. and Kato, A.C. (2000) IAP
family proteins delay motoneuron cell death in vivo. Eur. J. Neurosci., 12,
2059–2067.
37. Perrelet, D., Perrin, F.E., Liston, P., Korneluk, R.G., MacKenzie, A.,
Ferrer-Alcon, M. and Kato, A.C. (2004) Motoneuron resistance to
apoptotic cell death in vivo correlates with the ratio between X-linked
inhibitor of apoptosis proteins (XIAPs) and its inhibitor, XIAP-associated
factor 1. J. Neurosci., 24, 3777–3785.
38. Malaspina, A., Kaushik, N. and de Belleroche, J. (2001) Differential
expression of 14 genes in amyotrophic lateral sclerosis spinal cord
detected using gridded cDNA arrays. J. Neurochem., 77, 132–145.
39. Nomura, M., Shimizu, S., Sugiyama, T., Narita, M., Ito, T., Matsuda, H.
and Tsujimoto, Y. (2003) 14-3-3 Interacts directly with and negatively
regulates Pro-apoptotic Bax. J. Biol. Chem., 278, 2058–2065.
40. Kawamoto, Y., Akiguchi, I., Nakamura, S. and Budka, H. (2004) 14-3-3
Proteins in Lewy body-like hyaline inclusions in patients with sporadic
amyotrophic lateral sclerosis. Acta Neuropathol. (Berl), 108, 531–537.
41. Hubbell, E., Liu, W.M. and Mei, R. (2002) Robust estimators for
expression analysis. Bioinformatics, 18, 1585–1592.
42. Liu, W.M., Mei, R., Di, X., Ryder, T.B., Hubbell, E., Dee, S.,
Webster, T.A., Harrington, C.A., Ho, M.H., Baid, J. and Smeekens, S.P.
(2002) Analysis of high density expression microarrays with signed-rank
call algorithms. Bioinformatics, 18, 1593–1599.
43. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N.,
De Paepe, A. and Speleman, F. (2002) Accurate normalization of
real-time quantitative RT–PCR data by geometric averaging of multiple
internal control genes. Genome Biol., 3, research0034.
3320 Human Molecular Genetics, 2005, Vol. 14, No. 21
